• hepatic
  • Autosomal recessive polycystic kidney disease (ARPKD) is a rare but frequently severe disorder that is typically characterized by cystic kidneys and congenital hepatic fibrosis but displays pronounced phenotypic heterogeneity. (biomedcentral.com)
  • coronary
  • We performed this analysis to determine whether pravastatin reduced the rate of kidney function loss over ≈5 years in people with or at high risk for coronary disease. (ahajournals.org)
  • A recent publication suggested that pravastatin reduced rates of kidney function loss in humans with renal insufficiency and concomitant coronary disease, especially in those with proteinuria or more advanced renal impairment. (ahajournals.org)
  • The purpose of the present analysis was to determine the effect of pravastatin on rates of kidney function loss in a large group of subjects with or at high risk for coronary disease, with particular emphasis on those with concomitant moderate CKD, as defined by an estimated glomerular filtration rate (GFR) between 30 and 59.9 mL/min per 1.73 m 2 . (ahajournals.org)
  • Pravastatin is also used to lower the risk of stroke, heart attack, and other heart complications in people with or without coronary heart disease or other risk factors. (peacehealth.org)
  • Recently completed regression studies (PLAC I, PLACII, KAPS and REGRESS) show that pravastatin slows progression of atherosclerosis and lowers the incidence of coronary events in patients with mild to moderately severe hypercholesterolaemia and known coronary heart disease. (springer.com)
  • Large scale primary (WOSCOPS) and secondary (CARE) prevention studies, moreover, demonstrate that pravastatin has beneficial effects on coronary morbidity and mortality. (springer.com)
  • The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40 mg daily (a common starting dose) and those receiving usual care. (wikipedia.org)
  • genes
  • This study evaluates the impact of irbesartan (an AII-RB which acts similar to an ACEinh) and pravastatin on the clinical progression of chronic rejection and on the expression of TGF-beta, PDGF, and connective tissue genes in the chronically rejecting kidney. (clinicaltrials.gov)
  • disease
  • Autosomal recessive polycystic kidney disease (ARPKD) is a rare, but severe form of polycystic kidney disease with unexplained phenotypic variability and a considerable impact on affected patients and families as well as attending physicians. (biomedcentral.com)
  • This condition may be more likely to occur in older adults and in people who have kidney disease or poorly controlled hypothyroidism (underactive thyroid). (peacehealth.org)
  • generic
  • The U.S. Food and Drug Administration approved generic pravastatin for sale in the United States for the first time on April 24, 2006. (wikipedia.org)
  • clinical
  • While large clinical trials for the frequent and mostly adult onset autosomal dominant polycystic kidney diseases have recently been conducted, therapeutic initiatives for ARPKD are facing the challenge of small and clinically variable cohorts for which reliable end points are hard to establish. (biomedcentral.com)
  • drugs
  • The purpose of this study is to see how effective 2 drugs, irbesartan and pravastatin, are at slowing kidney transplant failure. (clinicaltrials.gov)
  • Using pravastatin with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. (drugs.com)
  • studies
  • Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of pravastatin in children 8 to 18 years of age. (drugs.com)
  • Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of pravastatin in the elderly. (drugs.com)
  • Pravastatin is generally well tolerated by most patients (including the elderly), as evidenced by data from studies of up to 5 years in duration. (springer.com)